Fibrotic Foundation: From Structural Rigidity to Functional Stasis Progressive intestinal fibrosis in SSc is driven by microvascular injury, oxidative stress, and aberrant cytokine signaling mediated by transforming growth factor- (TGF-), connective tissue growth factor (CTGF), and platelet-derived growth factor (PDGF) [13,14,15]
Cagrilintide is a long-acting amylin analogue peptide developed to complement modern metabolic therapies through a mechanism that differs from GLP-based compounds
Although LA is targeted specifically to the GI tract due to its nonabsorbed nature, understanding how long various formulations of the drug take to reach specific regions within the small intestine and in therapeutically effective concentrations are crucial for its use in other clinical conditions
In summary, no head to head studies exist at the moment
It remains investigational